At ESMO 2014, Prof Jonathan Ledermann (University College London, UK) provides an update on the management of ovarian cancer, including maintenance therapy with the poly ADP-ribose polymerase (PARP) inhibitor, olaparib, for BRCA-mutated ovarian cancer; anti-angiogenic agents, such as cediranib; and immunomodulatory drugs, such as immune checkpoint inhibitors.
ESMO 2014: Inhibition of PARP, angiogenesis and immune checkpoints for ovarian cancer management
16th March 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now